ASP Isotopes (ASPI) Expected to Announce Earnings on Monday

Key Points

• ASP Isotopes is set to release its Q2 2025 earnings on August 18th, expected to show a loss of $0.11 per share and revenue of $1.60 million.
• The stock price of ASP Isotopes recently opened at $9.32, with analysts noting a price target increase from $8.50 to $11.00 by Canaccord Genuity.
• An institutional investor raised its stake in ASP Isotopes by 9.4%, bringing total institutional ownership to 16.80% of the company’s shares.

ASP Isotopes (NASDAQ:ASPI - Get Free Report) is anticipated to issue its Q2 2025 quarterly earnings data before the market opens on Monday, August 18th. Analysts expect the company to announce earnings of ($0.11) per share and revenue of $1.60 million for the quarter.

ASP Isotopes (NASDAQ:ASPI - Get Free Report) last released its quarterly earnings data on Monday, August 18th. The company reported ($1.03) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.92). ASP Isotopes had a negative return on equity of 88.40% and a negative net margin of 767.86%. The company had revenue of $1.20 million for the quarter, compared to analyst estimates of $1.60 million. On average, analysts expect ASP Isotopes to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

ASP Isotopes Stock Down 8.1%

ASPI stock traded down $0.86 during midday trading on Friday, reaching $9.72. 3,424,649 shares of the company were exchanged, compared to its average volume of 3,018,670. The company has a debt-to-equity ratio of 0.80, a quick ratio of 7.17 and a current ratio of 7.21. ASP Isotopes has a 1-year low of $1.95 and a 1-year high of $11.68. The stock's 50-day simple moving average is $8.63 and its 200 day simple moving average is $6.62. The company has a market cap of $815.09 million, a price-to-earnings ratio of -15.99 and a beta of 3.36.

Analyst Ratings Changes

Separately, Canaccord Genuity Group raised their price objective on shares of ASP Isotopes from $8.50 to $11.00 and gave the stock a "buy" rating in a report on Wednesday, May 21st.

Hedge Funds Weigh In On ASP Isotopes

A number of institutional investors have recently modified their holdings of ASPI. BNP Paribas Financial Markets increased its holdings in shares of ASP Isotopes by 84.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company's stock valued at $41,000 after acquiring an additional 2,548 shares during the period. New York State Common Retirement Fund increased its holdings in shares of ASP Isotopes by 418.2% in the 2nd quarter. New York State Common Retirement Fund now owns 17,100 shares of the company's stock valued at $126,000 after acquiring an additional 13,800 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of ASP Isotopes by 9.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,613 shares of the company's stock valued at $148,000 after acquiring an additional 2,709 shares during the period. The Manufacturers Life Insurance Company increased its holdings in shares of ASP Isotopes by 9.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,840 shares of the company's stock valued at $153,000 after acquiring an additional 1,878 shares during the period. Finally, XTX Topco Ltd acquired a new position in shares of ASP Isotopes in the 2nd quarter valued at $178,000. 16.80% of the stock is owned by institutional investors and hedge funds.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.